Given that 6.9 months was the reported median PFS for the combination therapy of Chemo+ICI plus IBI305 among patients with EGFR-mutated NSCLC who progressed on EGFR-TKIs in the ORIENT-31 study,19 we developed model 1 to predict the likelihood of achieving a PFS of ≥9.0 months (using the median PFS as the positive predictive value) with Chemo+ICIs. Here, EGFR is linked to non-small cell lung carcinoma.